Additionally, a large study analyzing serum lipid levels in 415 PD patients—with and without GBA1 mutations—reported elevated levels of monohexosylceramides, Cer and SMs in mutation carriers [59]. This evidence concerns the gene GBA1 and Parkinson disease.